This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Pharmaceuticals (AVEO)

Q2 2012 Earnings Call

August 02, 2012 10:00 am ET


Monique Allaire

Tuan Ha-Ngoc - Chief Executive Officer, President and Director

William J. Slichenmyer - Chief Medical Officer

David B. Johnston - Chief Financial Officer and Principal Accounting Officer

Michael P. Bailey - Chief Commercial Officer


John S. Sonnier - William Blair & Company L.L.C., Research Division

Adnan S. Butt - RBC Capital Markets, LLC, Research Division

Anupam Rama - JP Morgan Chase & Co, Research Division

Marshall Urist - Morgan Stanley, Research Division

Thomas Wei - Jefferies & Company, Inc., Research Division

Salveen J. Richter - Canaccord Genuity, Research Division

Howard Liang - Leerink Swann LLC, Research Division



Good day, ladies and gentlemen, and welcome to the AVEO Oncology Second Quarter 2012 Financial Results Conference Call. My name is Derek, and I'll be your operator for today. [Operator Instructions] As a reminder, this conference is the recorded for replay purposes. I would now like to turn the conference over to Ms. Monique Allaire, Director of Investor Relations. Please proceed.

Monique Allaire

Thank you, Derek, and good morning, everyone. Today, we'll be talking about our second quarter 2012 financial results and key recent developments and achievements. With me are Tuan Ha-Ngoc, our President and Chief Executive Officer; Bill Slichenmyer, our Chief Medical Officer; and David Johnston, our Chief Financial Officer. In addition, joining us for the Q&A session will be Michael Bailey, our Chief Commercial Officer; and Elan Ezickson, our Executive Vice President and Chief Operating Officer.

The press release issued earlier today detailing our results is available on our website at

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs